Kidney Res Clin Pract.  2023 Sep;42(5):591-605. 10.23876/j.krcp.22.146.

Serum and urine metabolomic biomarkers for predicting prognosis in patients with immunoglobulin A nephropathy

Affiliations
  • 1Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
  • 2Department of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan, Republic of Korea
  • 3Department of Pharmacology, Pusan National University School of Medicine, Yangsan, Republic of Korea
  • 4Division of Nephrology, Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea
  • 5Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea

Abstract

Background
Immunoglobulin A nephropathy (IgAN) is the most prevalent form of glomerulonephritis worldwide. Prediction of disease progression in IgAN can help to provide individualized treatment based on accurate risk stratification. Methods: We performed proton nuclear magnetic resonance-based metabolomics analyses of serum and urine samples from healthy controls, non-progressor (NP), and progressor (P) groups to identify metabolic profiles of IgAN disease progression. Metabolites that were significantly different between the NP and P groups were selected for pathway analysis. Subsequently, we analyzed multivariate area under the receiver operating characteristic (ROC) curves to evaluate the predictive power of metabolites associated with IgAN progression. Results: We observed several distinct metabolic fingerprints of the P group involving the following metabolic pathways: glycolipid metabolism; valine, leucine, and isoleucine biosynthesis; aminoacyl-transfer RNA biosynthesis; glycine, serine, and threonine metabolism; and glyoxylate and dicarboxylate metabolism. In multivariate ROC analyses, the combinations of serum glycerol, threonine, and proteinuria (area under the curve [AUC], 0.923; 95% confidence interval [CI], 0.667–1.000) and of urinary leucine, valine, and proteinuria (AUC, 0.912; 95% CI, 0.667–1.000) showed the highest discriminatory ability to predict IgAN disease progression. Conclusion: This study identified serum and urine metabolites profiles that can aid in the identification of progressive IgAN and proposed perturbed metabolic pathways associated with the identified metabolites.

Keyword

Disease progression; IgA nephropathy; Metabolic networks and pathways; Metabolomics
Full Text Links
  • KRCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr